When Healing Becomes Harm
Fibrosis is the medical term for pathological scarring — when the body produces too much of a structural protein called collagen, stiffening and thickening tissue until the organ can no longer function normally.
It plays a role in some of the most serious complications of autoimmune diseases: the lung damage in rheumatoid arthritis (RA), the gut scarring in Crohn's disease, the gland destruction in Sjögren's disease (an autoimmune condition affecting moisture-producing glands), and the nerve and tissue damage in multiple sclerosis (MS). Fibrosis is also a major contributor to organ failure in diseases like pulmonary fibrosis and liver cirrhosis. It is responsible for up to 45% of deaths in developed countries, when all fibrosis-related diseases are counted together.
The Body's Repair System Gone Wrong
Normally, when tissue is injured, the immune system sends in inflammatory cells to fight infection and begin repair. Then, once the damage is controlled, a second wave of signals tells those cells to stand down. Specialized cells called fibroblasts build new connective tissue to patch the wound. Then they, too, are supposed to stop.
In fibrosis, that stop signal fails. The fibroblasts keep activating, keep producing collagen, keep remodeling tissue — long after the original injury is gone. And in autoimmune diseases, the immune system keeps feeding the fire. Persistent immune activity keeps signaling fibroblasts to stay active, creating a cycle that's very hard to break.
Think of it like a construction crew that was called in to fix a pothole but never got the message to stop. They keep paving, over and over, until the road is a wall.
The Molecular Switches Behind the Damage
A review published in Frontiers in Medicine digs into the specific molecular pathways that drive this process.
The central player is TGF-β (transforming growth factor beta) — a signaling molecule that acts like a master switch for fibrosis. When TGF-β binds to its target, it activates a chain of proteins called SMAD proteins, which travel into the cell nucleus and turn on genes for collagen production, scarring proteins, and tissue stiffening. Supporting pathways — including ones known as RAS-ERK and PI3K-AKT-mTOR — amplify and sustain this signal.
The review also highlights the role of epigenetic changes — alterations to how genes are read, without changing the DNA itself. In fibrosis, non-coding RNA molecules (tiny genetic regulators that don't code for proteins) and chemical modifications to histones (the proteins DNA wraps around) can lock fibroblasts in a permanently active state. This means even if the immune stimulus is removed, the fibroblasts may keep scarring on their own.
This does not mean new therapies targeting these pathways are ready for clinical use — most are still in laboratory or early-phase research.
What Makes Autoimmune Fibrosis Unique
In autoimmune diseases, the immune system never fully resolves its attack. Immune cells — particularly T cells and macrophages — continuously release inflammatory cytokines (chemical messengers) that feed directly into the TGF-β pathway. Immune cells and fibroblasts communicate constantly, each driving the other in a self-reinforcing loop.
This is why simply treating the inflammation, without also targeting the fibroblasts, may not be enough. And why treating fibroblasts without controlling the underlying immune activity may also fall short.
What's Being Explored
The review surveys emerging therapeutic approaches aimed at interrupting this loop. These include drugs that directly inhibit TGF-β signaling, agents that target the epigenetic changes keeping fibroblasts active, and mechanobiological approaches — therapies that work by changing the physical properties of the tissue environment rather than targeting specific molecules.
Combining immune modulation (calming the immune attack) with epigenetic reprogramming (resetting fibroblast behavior) and mechanical interventions represents the direction the field is heading — though no such combination has yet been validated in clinical trials for fibrosis in autoimmune diseases.
If you have an autoimmune condition that has been complicated by organ damage or scarring, this research is unlikely to change your immediate treatment options. However, it illustrates why so many researchers are now focused on fibrosis as a target in its own right, separate from controlling the immune response. For patients with diseases like RA or Crohn's, new drugs targeting fibrotic pathways could eventually become part of the treatment picture.
Honest Limitations
This paper is a narrative review — a synthesis of existing literature, not a new clinical study. The findings summarized are drawn from a mix of animal studies, lab models, and human clinical research at varying stages of maturity. The leap from molecular pathway to approved therapy is long and uncertain.
The authors call for better biomarkers — measurable signals in blood or tissue — that can identify which patients are at highest risk of developing fibrosis, and which molecular pathway is driving it. With biomarkers, clinical trials can be designed for the right patients at the right time — the same design challenge facing many complex chronic diseases. Combination therapies that target both the immune system and the fibroblasts are likely to be the next frontier, and several are now entering early-phase trials.